QSAM Biosciences Inc. , a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, announced today that the Japan Patent Office has granted a key patent that protects the use of “lower specific activity” Samarium-153 in conjunction with the treatment of bone cancer in children and adults.

This patent covers within the Japanese market the “high purity therapeutic bone agents” technology exclusively licensed to QSAM on a worldwide basis, and relates to the novel manner in which the Samarium-153 used in CycloSam® is produced. That process reduces long-lived impurities -- namely Europium-154 -- which may allow for higher and multiple dosing regimens in the treatment of different types of bone cancer, including cancer that has metastasized from the lung, breast or prostate. Those types of metastasized bone cancer are the subject of QSAM’s current FDA-cleared Phase 1 clinical trial, which has already begun recruiting and screening patients. QSAM believes that multi-dosing regimens may be the key to CycloSam® being able to successfully treat bone tumors, and is advancing it clinical trials toward that goal.

To read more please visit:

QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®

Source: QSAM Biosciences